{"id":"monotherapy-of-medium-dose-ics","safety":{"commonSideEffects":[{"rate":"5-10","effect":"Oropharyngeal candidiasis"},{"rate":"5-10","effect":"Dysphonia / hoarseness"},{"rate":"1-5","effect":"Tremor"},{"rate":"5-15","effect":"Headache"},{"rate":"5-10","effect":"Throat irritation"}]},"_chembl":{"chemblId":"CHEMBL2108659","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"ICS agents bind to glucocorticoid receptors in airway epithelial and immune cells, suppressing the transcription of pro-inflammatory cytokines, chemokines, and adhesion molecules. This reduces eosinophil recruitment, mucus production, and airway hyperresponsiveness. Medium-dose ICS monotherapy is used as maintenance therapy to control persistent asthma symptoms and prevent exacerbations.","oneSentence":"Medium-dose inhaled corticosteroid (ICS) monotherapy reduces airway inflammation by suppressing local immune responses and decreasing inflammatory mediator production in the lungs.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:34:39.755Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Persistent asthma maintenance therapy"},{"name":"Asthma control and exacerbation prevention"}]},"trialDetails":[{"nctId":"NCT01147510","phase":"PHASE4","title":"Asthma Control in Elderly Patients With Montelukast","status":"COMPLETED","sponsor":"Ajou University School of Medicine","startDate":"2010-07","conditions":"Persistent Asthma, Elderly","enrollment":140}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":9,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Monotherapy of medium dose ICS","genericName":"Monotherapy of medium dose ICS","companyName":"Ajou University School of Medicine","companyId":"ajou-university-school-of-medicine","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Medium-dose inhaled corticosteroid (ICS) monotherapy reduces airway inflammation by suppressing immune cell activation and inflammatory mediator production in the lungs. Used for Persistent asthma maintenance therapy (mild-to-moderate persistent asthma).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}